I Jeremias
Overview
Explore the profile of I Jeremias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1041
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ehrhardt H, Hacker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, et al.
Oncogene
. 2024 Jul;
43(32):2490.
PMID: 38965344
No abstract available.
2.
Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, et al.
Leukemia
. 2020 Dec;
35(1):294.
PMID: 33262529
No abstract available.
3.
Moretti A, Fonteyne L, Giesert F, Hoppmann P, Meier A, Bozoglu T, et al.
Nat Med
. 2020 Jan;
26(2):207-214.
PMID: 31988462
Frameshift mutations in the DMD gene, encoding dystrophin, cause Duchenne muscular dystrophy (DMD), leading to terminal muscle and heart failure in patients. Somatic gene editing by sequence-specific nucleases offers new...
4.
Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, et al.
Leukemia
. 2017 Dec;
32(4):1049-1052.
PMID: 29209043
No abstract available.
5.
Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, et al.
Leukemia
. 2017 Sep;
32(2):313-322.
PMID: 28895560
The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but...
6.
Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger F, Kohnke T, et al.
Leukemia
. 2015 Aug;
30(2):484-91.
PMID: 26239198
Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells. We tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute myeloid leukemia...
7.
Alsadeq A, Strube S, Krause S, Carlet M, Jeremias I, Vokuhl C, et al.
Leukemia
. 2015 Jun;
29(12):2307-16.
PMID: 26104660
P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β...
8.
Sandhofer N, Metzeler K, Rothenberg M, Herold T, Tiedt S, Groiss V, et al.
Leukemia
. 2014 Oct;
29(4):828-38.
PMID: 25322685
In acute myeloid leukemia (AML), several signaling pathways such as the phosphatidylinositol-3-kinase/AKT and the mammalian target of rapamycin (PI3K/AKT/mTOR) pathway are deregulated and constitutively activated as a consequence of genetic...
9.
Ehrhardt H, Wachter F, Grunert M, Jeremias I
Cell Death Dis
. 2013 Jun;
4:e661.
PMID: 23744361
Resting tumor cells represent a huge challenge during anticancer therapy due to their increased treatment resistance. TNF-related apoptosis-inducing ligand (TRAIL) is a putative future anticancer drug, currently in phases I...
10.
Ehrhardt H, Pannert L, Pfeiffer S, Wachter F, Amtmann E, Jeremias I
Br J Pharmacol
. 2012 Nov;
168(7):1558-69.
PMID: 23186127
Background And Purpose: In polychemotherapy protocols, that is for treatment of neuroblastoma and Ewing sarcoma, Vinca alkaloids and cell cycle-arresting drugs are usually administered on the same day. Here we...